0001415889-22-012355.txt : 20221209
0001415889-22-012355.hdr.sgml : 20221209
20221209180025
ACCESSION NUMBER: 0001415889-22-012355
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20221207
FILED AS OF DATE: 20221209
DATE AS OF CHANGE: 20221209
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Eldridge George A
CENTRAL INDEX KEY: 0001413006
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40544
FILM NUMBER: 221455807
MAIL ADDRESS:
STREET 1: C/O TARGANTA THERAPEUTICS CORPORATION
STREET 2: 222 THIRD STREET SUITE 2300
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Aerovate Therapeutics, Inc.
CENTRAL INDEX KEY: 0001798749
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 831377888
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 930 WINTER STREET
STREET 2: SUITE M-500
CITY: WALTHAM
STATE: MA
ZIP: 02451
BUSINESS PHONE: 617-443-2400
MAIL ADDRESS:
STREET 1: 930 WINTER STREET
STREET 2: SUITE M-500
CITY: WALTHAM
STATE: MA
ZIP: 02451
4
1
form4-12092022_061201.xml
X0306
4
2022-12-07
0001798749
Aerovate Therapeutics, Inc.
AVTE
0001413006
Eldridge George A
C/O AEROVATE THERAPEUTICS, INC.
930 WINTER STREET, SUITE M-500
WALTHAM
MA
02451
false
true
false
false
SEE REMARKS
Common Stock
2022-12-07
4
M
0
11637
2.14
A
13597
D
Common Stock
2022-12-07
4
S
0
7079
19.3657
D
6518
D
Common Stock
2022-12-07
4
S
0
4558
20.4021
D
1960
D
Common Stock
2022-12-08
4
M
0
12011
2.14
A
13971
D
Common Stock
2022-12-08
4
S
0
960
20.1185
D
13011
D
Common Stock
2022-12-08
4
S
0
20
20.58
D
12991
D
Common Stock
2022-12-08
4
S
0
11031
24.2022
D
1960
D
Stock Option (Right to Buy)
2.14
2022-12-07
4
M
0
11637
0
D
2031-04-01
Common Stock
11637
84656
D
Stock Option (Right to Buy)
2.14
2022-12-08
4
M
0
1887
0
D
2031-04-01
Common Stock
1887
82769
D
Stock Option (Right to Buy)
2.14
2022-12-08
4
M
0
10124
0
D
2031-04-01
Common Stock
10124
40726
D
This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 15, 2022.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $19.00 to $19.97, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $20.02 to $20.56, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $19.575 to $20.54, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $24.00 to $24.50, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
A total of 98,676 shares subject to an employee stock option were granted on April 2, 2021, with 25% of this option vested on June 4, 2022, and the remainder vesting in 36 substantially equal monthly installments thereafter.
A total of 50,850 shares subject to an employee stock option were granted on April 2, 2021, with 25% of this option vested on March 22, 2022, and the remainder vesting in 36 substantially equal monthly installments thereafter.
Officer Title: Chief Financial Officer and Treasurer
/s/ George A. Eldridge
2022-12-09